Eva Muñoz‐Couselo

4.8k total citations · 2 hit papers
89 papers, 2.1k citations indexed

About

Eva Muñoz‐Couselo is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Eva Muñoz‐Couselo has authored 89 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Oncology, 34 papers in Molecular Biology and 19 papers in Cancer Research. Recurrent topics in Eva Muñoz‐Couselo's work include Cancer Immunotherapy and Biomarkers (49 papers), Melanoma and MAPK Pathways (23 papers) and CAR-T cell therapy research (23 papers). Eva Muñoz‐Couselo is often cited by papers focused on Cancer Immunotherapy and Biomarkers (49 papers), Melanoma and MAPK Pathways (23 papers) and CAR-T cell therapy research (23 papers). Eva Muñoz‐Couselo collaborates with scholars based in Spain, United States and France. Eva Muñoz‐Couselo's co-authors include Javier Cortés, José Manuel Pérez-García, Seock‐Ah Im, Carolina Ortiz, Vassiliki Karantza, Rebecca Dent, Esther Zamora, Peter Schmid, Joohyuk Sohn and Anthony Gonçalvès and has published in prestigious journals such as Nature, Nature Communications and Nature Genetics.

In The Last Decade

Eva Muñoz‐Couselo

78 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

2021 330 citations Seock‐Ah Im, Eva Muñoz‐Couselo et al. profile →
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

2020 279 citations Peter Schmid, Roberto Salgado et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Eva Muñoz‐Couselo Spain	20	1.6k	598	574	446	418	89	2.1k
Maria Toki United States	15	1.0k 0.6×	546 0.9×	732 1.3×	240 0.5×	391 0.9×	33	1.7k
Maria Giovanna Dal Bello Italy	27	1.3k 0.8×	636 1.1×	332 0.6×	509 1.1×	861 2.1×	86	2.1k
Patrick G. Pilié United States	13	1.1k 0.7×	1.1k 1.8×	227 0.4×	342 0.8×	407 1.0×	43	1.8k
Ngocdiep T. Le United States	12	1.1k 0.7×	1.3k 2.1×	261 0.5×	346 0.8×	302 0.7×	29	1.9k
Wiam Bshara United States	25	746 0.5×	811 1.4×	314 0.5×	402 0.9×	328 0.8×	73	1.7k
Andreas Schneeweiss United States	2	2.4k 1.5×	559 0.9×	889 1.5×	731 1.6×	852 2.0×	3	3.0k
Jon Zugazagoitia Spain	20	1.1k 0.7×	370 0.6×	436 0.8×	172 0.4×	556 1.3×	74	1.6k
Elisa Espinet Germany	12	1.3k 0.8×	947 1.6×	383 0.7×	595 1.3×	263 0.6×	18	2.1k
Tobias Zellweger Switzerland	26	1.1k 0.7×	1.2k 2.1×	251 0.4×	709 1.6×	823 2.0×	51	2.4k
Darren Hodgson United Kingdom	21	2.3k 1.4×	1.4k 2.3×	249 0.4×	498 1.1×	782 1.9×	73	3.1k

Countries citing papers authored by Eva Muñoz‐Couselo

Since Specialization

Citations

This map shows the geographic impact of Eva Muñoz‐Couselo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Muñoz‐Couselo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Muñoz‐Couselo more than expected).

Fields of papers citing papers by Eva Muñoz‐Couselo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Muñoz‐Couselo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Muñoz‐Couselo. The network helps show where Eva Muñoz‐Couselo may publish in the future.

Co-authorship network of co-authors of Eva Muñoz‐Couselo

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Muñoz‐Couselo. A scholar is included among the top collaborators of Eva Muñoz‐Couselo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Muñoz‐Couselo. Eva Muñoz‐Couselo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Muñoz‐Couselo, Eva, L. A. Fernández, Miguel‐Ángel Berciano‐Guerrero, et al.. (2025). Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801). Clinical & Translational Oncology. 28(1). 320–329.

González‐Cao, María, Teresa Puértolas, José Luís Zamora Manzano, et al.. (2024). Access to melanoma drugs in Spain: a cross-sectional survey. Clinical & Translational Oncology. 26(10). 2572–2583. 3 indexed citations

Usset, Joseph, Axel Rosendahl Huber, Maria Andrianova, et al.. (2024). Five latent factors underlie response to immunotherapy. Nature Genetics. 56(10). 2112–2120. 11 indexed citations

González‐Cao, María, Teresa Puértolas, José Luís Zamora Manzano, et al.. (2024). Access to systemic treatment of non-melanoma skin cancer in Spain: a survey analysis. Clinical & Translational Oncology. 27(1). 386–391. 1 indexed citations

Márquez‐Rodas, Iván, et al.. (2024). SEOM-GEM clinical guidelines for cutaneous melanoma (2023). Clinical & Translational Oncology. 26(11). 2841–2855.

Bodet, D., Berta Ferrer-Rosell, Javier Hernández‐Losa, et al.. (2024). Mucosal Melanoma Clinical Management and Prognostic Implications: A Retrospective Cohort Study. Cancers. 16(1). 227–227. 6 indexed citations

Muñoz‐Couselo, Eva, Henri Montaudié, Miguel‐Ángel Berciano‐Guerrero, et al.. (2024). 1136P Cosibelimab in advanced cutaneous squamous cell carcinoma (CSCC): Longer-term efficacy and safety results from pivotal study. Annals of Oncology. 35. S745–S746. 1 indexed citations

Weiss, Sarah A., Mario Sznol, Montaser Shaheen, et al.. (2023). A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy. Clinical Cancer Research. 30(1). 74–81. 28 indexed citations

Quintana, Ángela, Vicente Peg, Aleix Prat, et al.. (2021). Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. European Journal of Cancer. 148. 134–145. 12 indexed citations

10.

Ortiz, Carolina, et al.. (2021). Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma. OncoTargets and Therapy. Volume 14. 3709–3719. 26 indexed citations

11.

Schmid, Peter, Roberto Salgado, Y.H. Park, et al.. (2020). Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. Annals of Oncology. 31(5). 569–581. 279 indexed citations breakdown →

12.

Hamid, Omid, Luciana Molinero, Christopher R. Bolen, et al.. (2019). Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clinical Cancer Research. 25(20). 6061–6072. 58 indexed citations

13.

Palafox, Marta, Touati Benoukraf, Patrick Jaynes, et al.. (2018). Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. The Journal of Experimental Medicine. 215(7). 1913–1928. 44 indexed citations

14.

García-Ruiz, Alonso, Juan Martín-Liberal, Cinta Hierro, et al.. (2018). Refining criteria of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) to improve clinical applicability. Annals of Oncology. 29. viii653–viii653. 5 indexed citations

15.

Ros, Javier & Eva Muñoz‐Couselo. (2018). DRESS syndrome due to vemurafenib treatment: switching BRAF inhibitor to solve a big problem. BMJ Case Reports. 2018. bcr–2018. 12 indexed citations

16.

Schmid, Peter, Yeon Hee Park, Eva Muñoz‐Couselo, et al.. (2017). Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): Preliminary results from KEYNOTE-173.. Journal of Clinical Oncology. 35(15_suppl). 556–556. 68 indexed citations

17.

Muñoz‐Couselo, Eva, et al.. (2017). NRAS-mutant melanoma: current challenges and future prospect. SHILAP Revista de lepidopterología. 10 indexed citations

18.

Pérez-García, José Manuel, et al.. (2017). Targeting FGFR pathway in breast cancer. The Breast. 37. 126–133. 83 indexed citations

19.

Serrano, César, Javier Cortés, Leticia De Mattos‐Arruda, et al.. (2011). Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Annals of Oncology. 23(4). 897–902. 112 indexed citations

20.

Cortés, Javier, Cristina Saura, Meritxell Bellet, et al.. (2010). HER2 and hormone receptor-positive breast cancer—blocking the right target. Nature Reviews Clinical Oncology. 8(5). 307–311. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact